APA

Lynce F., Barac A., Geng X., Dang C., Yu A. F., Smith K. L., Gallagher C., Pohlmann P. R., Nunes R., Herbolsheimer P., Warren R., Srichai M. B., Hofmeyer M., Cunningham A., Timothee P., Asch F. M., Shajahan-Haq A., Tan M. T., Isaacs C. & Swain S. M. (20191114). Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. : Breast cancer research and treatment.

Chicago

Lynce F, Barac A, Geng X, Dang C, Yu A F, Smith K L, Gallagher C, Pohlmann P R, Nunes R, Herbolsheimer P, Warren R, Srichai M B, Hofmeyer M, Cunningham A, Timothee P, Asch F M, Shajahan-Haq A, Tan M T, Isaacs C and Swain S M. 20191114. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. : Breast cancer research and treatment.

Harvard

Lynce F., Barac A., Geng X., Dang C., Yu A. F., Smith K. L., Gallagher C., Pohlmann P. R., Nunes R., Herbolsheimer P., Warren R., Srichai M. B., Hofmeyer M., Cunningham A., Timothee P., Asch F. M., Shajahan-Haq A., Tan M. T., Isaacs C. and Swain S. M. (20191114). Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. : Breast cancer research and treatment.

MLA

Lynce F, Barac A, Geng X, Dang C, Yu A F, Smith K L, Gallagher C, Pohlmann P R, Nunes R, Herbolsheimer P, Warren R, Srichai M B, Hofmeyer M, Cunningham A, Timothee P, Asch F M, Shajahan-Haq A, Tan M T, Isaacs C and Swain S M. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. : Breast cancer research and treatment. 20191114.